FY2029 EPS Estimates for IceCure Medical Cut by Analyst

IceCure Medical Ltd. (NASDAQ:ICCM) – Investment analysts at Brookline Capital Markets cut their FY2029 EPS estimates for IceCure Medical in a report issued on Tuesday, May 12th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn $0.05 per share for the year, down from their previous estimate of $0.08. The consensus estimate for IceCure Medical’s current full-year earnings is ($0.12) per share.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative return on equity of 222.27% and a negative net margin of 441.60%.The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $1.34 million.

A number of other analysts also recently issued reports on the stock. Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Finally, Alliance Global Partners initiated coverage on shares of IceCure Medical in a report on Monday, May 4th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $2.64.

IceCure Medical Stock Performance

NASDAQ ICCM opened at $0.24 on Thursday. IceCure Medical has a 52-week low of $0.22 and a 52-week high of $1.40. The company has a market capitalization of $19.24 million, a P/E ratio of -0.99 and a beta of 0.47. The company has a fifty day moving average of $0.42 and a 200-day moving average of $0.58.

Hedge Funds Weigh In On IceCure Medical

A number of hedge funds have recently modified their holdings of ICCM. Concurrent Investment Advisors LLC purchased a new position in shares of IceCure Medical in the fourth quarter valued at about $48,000. Jane Street Group LLC purchased a new position in shares of IceCure Medical in the fourth quarter valued at about $67,000. Finally, Virtu Financial LLC purchased a new position in shares of IceCure Medical in the fourth quarter valued at about $39,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.